Lamisilatt (Terbinafine Hydrochloride)

Terbinafine Hydrochloride is an allylamine antifungal that targets dermatophyte infections of the skin.

• Tinea pedis (athlete’s foot): Reduces fungal growth and alleviates itching, scaling and redness on the feet.
• Tinea corporis (ringworm): Clears skin lesions and prevents spread of infection on the body.
• Tinea cruris (jock itch): Relieves irritation and eliminates fungal colonies in the groin area.
• Other superficial fungal skin infections: Improves symptoms of cutaneous candidiasis and similar conditions.

• Terbinafine Hydrochloride inhibits the fungal enzyme squalene epoxidase, which blocks conversion of squalene to ergosterol. This leads to accumulation of toxic squalene within the fungal cell and depletion of ergosterol, a key component of the cell membrane, resulting in loss of membrane integrity and fungal cell death. The selective inhibition concentrates activity in dermatophytes while sparing human cells and is effective after repeated topical applications.

Topical terbinafine may cause local skin reactions, ranging from mild irritation to rare severe hypersensitivity.

Common Side Effects

• Itching or pruritus
• Burning sensation at the application site
• Redness or erythema

Serious or Rare Side Effects

• Severe allergic reaction (angioedema or anaphylaxis)
• Contact dermatitis with blistering
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Persistent swelling or ulceration of the skin

When using Lamisilatt, follow these safety measures:

• Avoid application on broken or inflamed skin: Do not apply to open wounds or irritated areas.
• Do not use if you have known hypersensitivity to terbinafine or other allylamines: discontinue immediately if a reaction occurs.
• Limit treatment to the prescribed area and duration: excessive use may increase irritation.
• Monitor for worsening symptoms: seek medical advice if infection does not improve within two weeks.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Terbinafine topical has limited systemic interactions, but consider the following:

Major Interactions (Avoid)

• Concurrent use of systemic terbinafine or other oral antifungals: may increase systemic exposure and risk of adverse reactions.
• Co‑application with other topical antifungal agents containing azoles: can cause increased skin irritation.

Moderate Interactions (Monitor Closely)

• Use with CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) if systemic absorption occurs: monitor for systemic side effects.
• Concurrent use of corticosteroid creams: may mask signs of infection, requiring close observation.
• Application with occlusive dressings: may enhance absorption and increase risk of irritation.